Alzheimer’s and brain imaging
Executive Summary
The role of brain imaging as an outcome measure in Phase III Alzheimer's Disease trials will be discussed at a joint meeting of FDA's Peripheral & Central Nervous System Drugs and Medical Imaging Drugs Advisory Committees Nov. 18. On Nov. 19, the committees will review Down State Medical's positron emission tomography agent F18 fluoro-D-glucose for imaging in Alzheimer's Disease. The meeting will take place at the Holiday Inn, Gaithersburg, Md...